CRVO NASDAQ
CervoMed Inc.
1W: -3.1%
1M: -16.9%
3M: -10.5%
YTD: -71.5%
1Y: -68.6%
3Y: -80.2%
5Y: -93.7%
$2.22
-0.02 (-0.89%)
Weekly Expected Move ±15.1%
$2
$2
$2
$3
$3
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -8.18.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-07-22
Earliest Filing
2025-05-12
Latest Filing
partner: 2
target: 2
acquirer: 1
Counterparties (Filed by CRVO)
5 relationshipsCompanies named in CRVO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Leerink Partners LLC | — | partner | Sales Agent for the at-the-market offering of common stock | 2025-05-12 | View |
| Diffusion Pharmaceuticals Inc. | — | acquirer | Parent company that acquired EIP Pharma, Inc. in a merger transaction. | 2023-09-29 | View |
| EIP Pharma, Inc. | — | target | Target company in the merger transaction that was acquired by Diffusion Pharmaceuticals Inc. | 2023-09-29 | View |
| EIP Pharma, Inc. | — | target | Target company in the merger agreement with Diffusion Pharmaceuticals Inc. | 2023-03-30 | View |
| BTIG, LLC | — | partner | Sales agent and/or principal for the At-The-Market Sales Agreement | 2022-07-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Regulation FD; Exhibits | View | |
| 2026-10-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-10-09 | Regulation FD; Exhibits | View | |
| 2026-09-28 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-10 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-08-04 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-09 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-22 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-06-22 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-18 | Other Events; Exhibits | View | |
| 2026-06-15 | Regulation FD; Exhibits | View | |
| 2026-06-10 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-06-09 | Shareholder Vote; Exhibits | View | |
| 2026-05-18 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-22 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-07 | Regulation FD; Exhibits | View | |
| 2026-03-23 | Regulation FD; Exhibits | View | |
| 2026-03-19 | Regulation FD; Other Events; Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR